Blockchain Registration Transaction Record

Quantum BioPharma Targets Neurological and Wellness Markets with Diversified Pipeline

Quantum BioPharma (QNTM) advances LUCID-MS for multiple sclerosis and unbuzzd(TM) for alcohol metabolism, targeting neurological and wellness markets as global neurological disease burden rises.

This news matters because neurological disorders are a growing global crisis, yet many current treatments only manage symptoms. Quantum BioPharma’s LUCID-MS aims to address the root cause of disability in multiple sclerosis, potentially improving quality of life for millions. Meanwhile, unbuzzd(TM) offers a practical solution for alcohol metabolism, appealing to health-conscious consumers. For investors, the company’s dual focus on high-need therapeutics and consumer wellness represents a balanced approach to growth in two rapidly expanding sectors.